Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years

Clinical Infectious Diseases

Volumn 58, Issue 3, 2014, Pages 413-422

  Nachman, Sharon ^a,k   Zheng, Nan ^b   Acosta, Edward P ^c   Teppler, Hedy ^d   Homony, Brenda ^d   Graham, Bobbie ^e   Fenton, Terence ^b   Xu, Xia ^d   Wenning, Larissa ^d   Spector, Stephen A ^f   Frenkel, Lisa M ^g   Alvero, Carmelita ^b   Worrell, Carol ^h   Handelsman, Edward ⁱ   Wiznia, Andrew ^j   Moultrie, Harry ^l   Kindra, Gurpreet ^l   Sanders, Margaret Ann ^l   Williams, Ruth ^l   Jensen, Jennifer ^l   Acevedo, Midnela ^l   Fabregas, Lizbeth ^l   Jurgrau, Andrea ^l   Foca, Marc ^l   Higgins, Alice ^l   Deville, Jaime G ^l   Nielsen Saines, Karin ^l   Carter, Michele F ^l   Swetnam, John ^l   Wilson, Joan ^l   Donnelly, Margaret ^l   Akleh, Siham ^l   Rigaud, Mona ^l   Kaul, Aditya ^l   Patel, Nehali ^l   Gaur, Aditya ^l   Utech, L Jill ^l   Cardoso, Edmundo ^l   Moreira, Ana Maria ^l   Santos, Breno ^l   Bobat, Raziya ^l   Mngqibisa, Rosie ^l   Burey, Marlene ^l   Abadi, Jacob ^l   Rosenberg, Michael ^l   Luzuriaga, Katherine ^l   Picard, Donna ^l   Pagano Therrien, Jessica ^l   Dittmer, Sylvia ^l   Ndiweni, Hilda Ntatule ^l   Patel, Amisha ^l   Delrey, Michelle ^l   McMullen Jackson, Chivon ^l   Paul, Mary E ^l   Melvin, Ann ^l   Venema Weiss, Corry ^l   Lane, Jenna ^l   Beneri, Christy ^l   Ferraro, Denise ^l   Infanzon, Erin ^l   McAuley, James B ^l   Aziz, Mariam ^l   McNichols, Maureen ^l   Pelton, Stephen ^l   McLaud, Deb ^l   Clarke, Diana ^l   Zeichner, Steven ^l   Akar, Arezou ^l   Thompson, Deidre ^l   Douglas, Steven D ^l   Rutstein, Richard M ^l   Vincent, Carol A ^l   Vachon, Mary Elizabeth ^l   Cavallo, Martha ^l   Purswani, Murli Udharam ^l   Masheto, Gaerolwe ^l   Ogwu, Anthony ^l   Kakhu, Tebogo ^l   Viani, Rolando M ^l   Darcey, Anita ^l   Norris, Kimberly ^l   Burchett, Sandra K ^l   Kneut, Catherine ^l   Karthas, Nancy ^l   Casey, Denise ^l   Emmanuel, Patricia ^l   Lujan Zilbermann, Jorge ^l   Rana, Sohail ^l   Houston, Patricia ^l   Mengistab, Mulu ^l   Rathore, Mobeen ^l   Mirza, Ayesha ^l   Gayton, Tabetha ^l   Barr, Emily ^l   Dunn, Jennifer ^l   Hahn, Kerry ^l   Eysallenne, Zulma ^l   Howard, F Sholar ^l   Graham, Kathleen ^l   Negra, Marinella Della ^l   Queiroz, Wladimir ^l   Lian, Yu Ching ^l   Wara, Diane ^l   Ruel, Ted ^l   Vandyke, Russell ^l   Reilly, Patricia ^l   Bradford, Sheila ^l   Van Rensburg, Anita Janse ^l   Dobbels, Els ^l   Bester, Marietjie ^l   Bamji, Mahrukh ^l   Paul, Santa ^l   Sarza, Mirala ^l   Kovacs, Andrea ^l   Homans, James ^l   Spencer, Lashonda ^l   Hofer, Cristna ^l   Abreu, Thalita ^l   Oliveira, Ricardo ^l   Joao, Esau C ^l   Pinto, Jorge ^l   Ferreira, Flavia ^l   Kakehasi, Fabiana ^l   Cervi, Maria Celia ^l   Isaac, Marcia De Lima ^l   Losso, Marcelo H ^l   Stankievich, Erica ^l   Foradori, Irene ^l   Tucker, Diane ^l   Church, Joseph ^l   Belzer, Marvin ^l   Hopkins, Johns ^l   Ellen, Jonathan ^l   Agwu, Allison ^l   Laurel, Borkovic ^l   more..

^a STONY BROOK UNIVERSITY   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^f RADY CHILDREN'S HOSPITAL   (United States)

^g SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^h EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

ⁱ NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^j JACOBI MEDICAL CENTER   (United States)

^k STONY BROOK UNIVERSITY   (United States)

^l NONE

more..

Author keywords

adverse event; pediatric HIV; pharmacokinetics; raltegravir

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CD4 ANTIGEN; DARUNAVIR; EFAVIRENZ; ETRAVIRINE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; RALTEGRAVIR; RITONAVIR; TENOFOVIR; VIRUS RNA;

ABNORMAL BEHAVIOR; ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; CD4 LYMPHOCYTE PERCENTAGE; CHEWABLE TABLET; CHILD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CLEARANCE; DRUG CONCENTRATION; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERACTIVITY; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MEDICATION COMPLIANCE; MONOTHERAPY; MULTICENTER STUDY; OPEN STUDY; PALATABILITY; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRESCHOOL CHILD; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REDUCTION; SCHOOL CHILD; TABLET; TABLET FORMULATION; TOXIC HEPATITIS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; YOUNG ADULT;

ADVERSE EVENT; PEDIATRIC HIV; PHARMACOKINETICS; RALTEGRAVIR;

ADMINISTRATION, ORAL; ADOLESCENT; ANTI-HIV AGENTS; CHILD; CHILD, PRESCHOOL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT; MALE; PYRROLIDINONES; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84892742221     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit696     Document Type: Article

References (9)

1. Steigbigel RT, Cooper DA, Kumar PN, et al. BENCHMRK Study Teams. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359:339-54.
2. Steigbigel RT, Cooper DA, Teppler H, et al. BENCHMRK Study Teams. Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 phase III trials. Clin Infect Dis 2010; 50:605-12.
3. Lennox JL, DeJesus E, Lazzarin A, et al. STARTMRK investigators. Safety and efficacyofraltegravir-based versus efavirenz-basedcombination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009; 374:796-806.
4. De Castro N, Braun J, Charreau I, et al. EASIER ANRS 138 study group. Switch from enfuvirtide to raltegravir in virologically suppressed multi-drug-resistant HIV-1-infected patients: a randomized open-label trial. Clin Infect Dis 2009; 49:1259-67.
5. Rockstroh JK, Lennox JL, Dejesus E, et al., STARTMRK Investigators. Long-term treatment with raltegravir or efavirenz combined with tenofo-vir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Clin Infect Dis 2011; 53:807-16.
6. Long MC, Bennetto-Hood C, Acosta EP. A sensitive HPLC-MS-MS method for the determination of raltegravir in human plasma. J Chro-matogr B Analyt Technol Biomed Life Sci 2008; 867:165-71.
7. Merschman SA, Vallano PT, Wenning LA, Matuszewski BK, Woolf EJ. Determination of the HIV integrase inhibitor, MK-0518 (raltegravir), in human plasma using 96-well liquid-liquid extraction and HPLC MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 857: 15-24.
8. Blanche S, Bologna R, Cahn P, et al. Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment-experienced children and adolescents. AIDS 2009; 23:2005-13.
9. Salazar JC, Cahn P, Yogev R, et al. Efficacy, safety and tolerability of ti-pranavir coadministered with ritonavir in HIV-1 infected children and adolescents. AIDS 2008; 22:1789-98.